×
Entertainment News
Technology News

ads

Teva Pharmaceutical Industries ADRs Edge Up Pre-Market as FDA Approves Use of QVAR With Dose Counter for Asthma Treatment

Teva Pharmaceutical Industries ADRs Edge Up Pre-Market as FDA Approves Use of QVAR With Dose Counter for Asthma Treatment

Teva Pharmaceutical Industries (TEVA) American depositary shares edged higher in Friday's pre-market session, after the Israel-based pharmaceutical company said the U.S. Food and Drug Administration approved the use of its QVAR(beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older.The dose counter is designed to help asthma patients and caregivers keep track of the number of doses remaining in the canister, Teva said, adding the new product will be commercially available later this year. TEVA was up 0.3% at $50.79 in recent pre-market trading, in a 52-week range of $36.26 to $54.70.

Teva Pharmaceutical Industries ADRs Edge Up Pre-Market as FDA Approves Use of QVAR With Dose Counter for Asthma Treatment

ads